Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-106355
Filing Date
2025-11-04
Accepted
2025-11-04 16:48:34
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6952
2 EXHIBIT 1 tm2529987d3_ex1.htm EX-1 5093
  Complete submission text file 0001104659-25-106355.txt   13752
Mailing Address BAARERSTRASSE 14 ZUG Switzerland
Business Address BAARERSTRASSE 14 ZUG Switzerland 6173154600
CRISPR Therapeutics AG (Subject) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89674 | Film No.: 251450255
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 200 CENTRAL AVENUE ST. PETERSBURG FL 33701
Business Address 200 CENTRAL AVENUE ST. PETERSBURG FL 33701 212-426-7040
ARK Investment Management LLC (Filed by) CIK: 0001697748 (see all company filings)

EIN.: 464309299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A